It has been reported that surface PD-L1 levels are low in prostate cancer cell lines and primary prostate tumor tissue, potentially explaining the general lack of therapeutic response to anti-PDL1 blockade (Martin et al., 2015; Zang et al., 2007). This evidence concerns the gene CD274 and Familial prostate cancer.